Nxera Pharma Co., Ltd. (SOLTF)
OTCMKTS
· Delayed Price · Currency is USD
5.91
-0.49 (-7.66%)
Apr 23, 2025, 4:00 PM EDT
Nxera Pharma Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 28,835 | 12,766 | 15,569 | 17,712 | 8,842 | Upgrade
|
| Revenue Growth (YoY) | 125.87% | -18.00% | -12.10% | 100.32% | -9.09% | Upgrade
|
| Cost of Revenue | 7,616 | 3,102 | 926 | 933 | 761 | Upgrade
|
| Gross Profit | 21,219 | 9,664 | 14,643 | 16,779 | 8,081 | Upgrade
|
| Selling, General & Admin | 12,924 | 8,167 | 3,535 | 3,138 | 2,525 | Upgrade
|
| Research & Development | 11,816 | 10,075 | 7,454 | 5,931 | 3,793 | Upgrade
|
| Other Operating Expenses | 12 | 23 | - | -2 | -1 | Upgrade
|
| Operating Expenses | 27,843 | 20,063 | 11,831 | 9,869 | 7,227 | Upgrade
|
| Operating Income | -6,624 | -10,399 | 2,812 | 6,910 | 854 | Upgrade
|
| Interest Expense | -769 | -787 | -673 | -518 | -207 | Upgrade
|
| Interest & Investment Income | 1,478 | 1,225 | 236 | 4 | 35 | Upgrade
|
| Earnings From Equity Investments | - | - | -429 | 50 | -356 | Upgrade
|
| Currency Exchange Gain (Loss) | 27 | -329 | 313 | 22 | -217 | Upgrade
|
| Other Non Operating Income (Expenses) | 1,288 | -282 | 696 | -3,105 | 1,402 | Upgrade
|
| EBT Excluding Unusual Items | -4,600 | -10,572 | 2,955 | 3,363 | 1,511 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1 | -46 | -1,877 | 208 | -18 | Upgrade
|
| Gain (Loss) on Sale of Assets | -63 | -62 | - | - | - | Upgrade
|
| Asset Writedown | - | - | - | -3,138 | 129 | Upgrade
|
| Pretax Income | -4,662 | -10,680 | 1,078 | 433 | 1,622 | Upgrade
|
| Income Tax Expense | 176 | -3,487 | 696 | -584 | 143 | Upgrade
|
| Earnings From Continuing Operations | -4,838 | -7,193 | 382 | 1,017 | 1,479 | Upgrade
|
| Net Income | -4,838 | -7,193 | 382 | 1,017 | 1,479 | Upgrade
|
| Net Income to Common | -4,838 | -7,193 | 382 | 1,017 | 1,479 | Upgrade
|
| Net Income Growth | - | - | -62.44% | -31.24% | 3.28% | Upgrade
|
| Shares Outstanding (Basic) | 90 | 83 | 82 | 81 | 79 | Upgrade
|
| Shares Outstanding (Diluted) | 90 | 83 | 83 | 82 | 79 | Upgrade
|
| Shares Change (YoY) | 8.74% | -0.09% | 0.71% | 3.16% | 2.60% | Upgrade
|
| EPS (Basic) | -53.92 | -87.17 | 4.67 | 12.53 | 18.78 | Upgrade
|
| EPS (Diluted) | -53.92 | -87.18 | 4.63 | 12.40 | 18.59 | Upgrade
|
| EPS Growth | - | - | -62.66% | -33.30% | 0.49% | Upgrade
|
| Free Cash Flow | -8,244 | -6,077 | 9,675 | 6,902 | 4,580 | Upgrade
|
| Free Cash Flow Per Share | -91.87 | -73.65 | 117.14 | 84.17 | 57.62 | Upgrade
|
| Gross Margin | 73.59% | 75.70% | 94.05% | 94.73% | 91.39% | Upgrade
|
| Operating Margin | -22.97% | -81.46% | 18.06% | 39.01% | 9.66% | Upgrade
|
| Profit Margin | -16.78% | -56.34% | 2.45% | 5.74% | 16.73% | Upgrade
|
| Free Cash Flow Margin | -28.59% | -47.60% | 62.14% | 38.97% | 51.80% | Upgrade
|
| EBITDA | -2,640 | -7,921 | 4,157 | 8,188 | 2,204 | Upgrade
|
| EBITDA Margin | -9.16% | -62.05% | 26.70% | 46.23% | 24.93% | Upgrade
|
| D&A For EBITDA | 3,984 | 2,478 | 1,345 | 1,278 | 1,350 | Upgrade
|
| EBIT | -6,624 | -10,399 | 2,812 | 6,910 | 854 | Upgrade
|
| EBIT Margin | -22.97% | -81.46% | 18.06% | 39.01% | 9.66% | Upgrade
|
| Effective Tax Rate | - | - | 64.56% | - | 8.82% | Upgrade
|
| Advertising Expenses | 2,238 | - | - | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.